Medtronic plc (NYSE:MDT) is one of the cheap robotics stocks to buy right now.
On May 20, Medtronic PLC (NYSE:MDT) reiterated plans to expand its care options for people struggling with chronic pain with the acquisition of SPR Therapeutics
The company is poised to pay $650 million to acquire all outstanding equity in SPR, underscoring its focus on deals that enhance its core franchises. The transaction is poised to close in the fall, within the first half of Medtronic’s Fiscal Year 2027, subject to regulatory approvals. The acquisition will enhance the company’s Neuromodulation portfolio with temporary peripheral nerve stimulation (PNS) technology.
Consequently, it will be well equipped to reach and support people with minimally invasive pain-relief options. Medtronic is to gain access to SPR’s SPRINT System, which provides pain relief without the need for permanent implants. In addition, the acquisition will enable the company to reach more patients with less-invasive pain relief solutions. “Our purpose first and foremost is to serve patients,” said Domenico De Paolis, Interim President, Neuromodulation, part of the Medtronic Neuroscience Portfolio. “That is why we continue to thoughtfully expand our pain intervention therapies.